Participated · Series B · Jun 2026

PhoenixAI builds an AI-native database designed to unify real-time and at-rest data into a single engine that offers speed, concurrency, and governance for agentic AI workloads. The company says its platform enables sub-second responses on live normalized data and supports streaming updates (e.g., from Kafka) becoming queryable within seconds. PhoenixAI reports production deployments at customers including AppLovin, Coinbase, Conductor, and Demandbase, which the company says see significant performance improvements on large-scale queries. The startup plans to use Series B proceeds to accelerate product development, expand go-to-market efforts, and strengthen governance capabilities for regulated industries. PhoenixAI is headquartered in Menlo Park, California and was formerly known as CelerData.

Participated · Series A · Jan 2026

Ventaris Surgical is a privately held med-tech firm focused on improving kidney stone surgery through a novel ureteroscopic system that minimizes friction in the procedure and helps surgeons attain consistent, complete stone clearance. The company asserts that current instruments make it difficult to reliably remove all stones because of anatomical variation, stone burden, workflow constraints, and surgeon fatigue. By redesigning the toolset, Ventaris intends to boost surgical outcomes while easing surgeon workload. Headquartered in San Carlos, California, the startup is still in the clinical development stage and has not disclosed commercial revenues or user metrics. It plans to use newly raised capital to advance clinical studies and achieve key regulatory and commercial milestones. Board expansion accompanies the financing, adding Varun Gupta (Longitude Capital) and Justin Klein (Vensana Capital) alongside independent director Amir Abolfathi.

Participated · Series A · Jun 2025

Parallel Bio has developed an organoid-based immune system platform that combines lymph-node organoids with AI and robotics to model human immune responses at scale. Its Clinical Trial in a Dish offering is being used by pharmaceutical partners to test safety and efficacy of immunotherapies and drugs across diverse human-derived organoids. The company has signed eight pharmaceutical partners, including three Fortune 500 companies, who are testing more than 50 drugs and immunotherapies on the platform. A reported preclinical study with partner Centivax validated broad humoral and T cell responses to its Centi‑Flu universal flu vaccine candidate and supported Centivax’s move to manufacturing for human trials. Parallel Bio plans to use the new capital to scale AI and automation, expand its scientific and engineering team, and support growing pharmaceutical partnerships. The company is based in Cambridge, Mass., and was founded in 2021. Parallel Bio developed an immune organoid platform that combines immune organoids, machine learning, and robotics to model human immune responses at population scale. The company says its platform can produce antibodies against any disease target in 21 days and has discovered eight human high‑affinity antibodies for cancer and infectious diseases. Parallel validated reproducible modeling across diverse patient backgrounds, built a large proprietary biobank, filed IP on key technologies, and demonstrated high‑throughput vaccine response screening. It plans to bring the immune platform to market with pharmaceutical and biotechnology partners to accelerate drug discovery and reduce reliance on animal testing. The company raised a $4.3 million seed round to accelerate commercialization and proof‑of‑concept work. Parallel positions its technology as able to shift drug development outcomes (claiming it can flip a 95% clinical‑trial failure rate toward success) and to enable discovery of organoid‑derived therapeutics and autoimmune disease models.

Led · Equity · Feb 2024

Buddy builds software to make insurance products easier to transact on the internet, according to CEO and co‑founder Charles Merritt. The company focuses on online insurance transaction software for insurers and other product providers. A recent capital infusion increases its ability to continue product development and distribution. The report says the company raised US$7 million in the cited round from 49 investors. That raise brings Buddy’s total funding to US$8 million. No operating metrics (revenue/users) or future product roadmaps were disclosed in the article. Buddy offers on-demand supplemental accident insurance designed for outdoor enthusiasts, with policies purchasable for terms from a day up to a year and instant delivery for immediate coverage. Premiums range from $9.72 per day to $600 per year, with separate family and kids plans and benefit payouts paid directly to consumers. Policies are sold and serviced via API, mobile and desktop web, and chat, and Buddy’s platform uses proprietary software and natural language programming to unify customer, partner, and carrier data. Coverage includes most outdoor and adventure sports and benefits can be used for ambulance rides, urgent care, emergency surgeries, gear repair, missed work, or childcare. The company is operational in several states (including AZ, CO, KY, NC, OH, TN, TX) and emphasizes fast enrollment (coverage in less than three minutes). Buddy plans to expand nationally to all 50 states and scale partner integrations and retention marketing.

Participated · Seed · Mar 2023

Lonestar is building infrastructure to house data centers in space, allowing customers to store and process information off-planet. The company believes that operating data centers beyond Earth will provide enhanced security, resiliency, and scalability for critical digital assets. Its core product centers on launching modular, space-qualified data-storage units, though detailed technical specifications have not been disclosed. In conjunction with its latest financing, Lonestar installed a new chief executive to steer the next stage of growth. The startup swiftly secured a $6.6 million seed-plus round, closing the deal in only 72 hours. With fresh capital in hand, management plans to accelerate engineering efforts and begin commercial pilots. Lonestar is already planning a larger Series A later this year to support full-scale deployment and market entry.